# A Study to Evaluate the Effect of the Potent CYP3A4 Inhibitor Itraconazole on the Pharmacokinetics (PK) of TAK-906 in Healthy Participants

> **NCT03161405** · PHASE1 · COMPLETED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 12 (actual)

## Conditions studied

- Healthy Participants

## Interventions

- **DRUG:** TAK-906 Maleate
- **DRUG:** Itraconazole

## Key facts

- **NCT ID:** NCT03161405
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-06-05
- **Primary completion:** 2017-07-02
- **Final completion:** 2017-07-10
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2019-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03161405

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03161405, "A Study to Evaluate the Effect of the Potent CYP3A4 Inhibitor Itraconazole on the Pharmacokinetics (PK) of TAK-906 in Healthy Participants". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03161405. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*